Background: Patients with locally advanced renal cell carcinoma (RCC) may experience recurrence after surgery. In the phase 3 KEYNOTE-564 (NCT03142334) trial, adjuvant pembrolizumab demonstrated ...

Powles TB, van der Heijden MS, Galsky MD, et al. A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive ...

Comparative restricted mean survival time (RMST) analysis of survival in advanced hepatocellular carcinoma (aHCC) from pivotal phase III trials: IMbrave-150, ORIENT-32, CARES-310, HIMALAYA, and CM-9DW ...

The median overall survival was 32 months in patients who received adjuvant chemotherapy and 26 months in patients who did not. Adjuvant multi-agent chemotherapy can improve overall survival (OS ...

Another trial is testing the same combination in patients with RCC, but with only 3 weeks of neoadjuvant therapy. These patients then go on to a sandwich therapy with adjuvant pembrolizumab. A ...

During a Targeted Oncology™ Community Case Forum™ event, Hans Hammers, MD, discussed trials that shed light on the role of adjuvant therapies for patients with stage II and III renal cell carcinoma.

Efficacy and safety of durvalumab and gemcitabine-based chemotherapy combined with or without lenvatinib in advanced biliary tract cancer. Comparative restricted mean survival time (RMST) analysis of ...

Systemic adjuvant treatment includes chemotherapy and radiotherapy. But the optimal scheduling is not known. Recently proposed sequential chemo-radiotherapy as sandwich therapy for high risk ...

SWZ The Swiss Helvetia Fund Inc.

We also explore the controversy surrounding CDK4/6 inhibitors in adjuvant breast cancer therapy and discuss the MARIPOSA data for EGFR-mutated NSCLC. Dato-DXd Wins an FDA Approval for HR+/HER2– Breast ...